Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ripretinib
Drug ID BADD_D02591
Description Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778]
Indications and Usage Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with [imatinib].[L13769]
Marketing Status approved
ATC Code L01EX19
DrugBank ID DB14840
KEGG ID D11353
MeSH ID C000707850
PubChem ID 71584930
TTD Drug ID D09AAK
NDC Product Code 59116-5331; 73207-101; 59116-5330; 59116-5332; 59116-5333
UNII 9XW757O13D
Synonyms ripretinib | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
Chemical Information
Molecular Formula C24H21BrFN5O2
CAS Registry Number 1442472-39-0
SMILES CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.002530%Not Available
Abdominal distension07.01.04.0010.000683%
Abdominal pain07.01.05.0020.001858%
Abdominal pain upper07.01.05.0030.003168%
Acne23.02.01.0010.000683%Not Available
Ageusia17.02.07.001; 07.14.03.0030.000358%Not Available
Alopecia23.02.02.0010.012122%
Amnesia19.20.01.001; 17.03.02.0010.000246%
Aphasia19.21.01.001; 17.02.03.0010.000112%
Arthralgia15.01.02.0010.002753%
Asthenia08.01.01.0010.002843%Not Available
Back pain15.03.04.0050.000873%
Blister23.03.01.001; 12.01.06.0020.001768%Not Available
Bone pain15.02.01.0010.000873%
Burning sensation17.02.06.001; 08.01.09.0290.000381%Not Available
Chest discomfort08.01.08.019; 22.12.02.002; 02.02.02.0090.000683%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000795%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.000112%Not Available
Constipation07.02.02.0010.005283%
Cough22.02.03.0010.000985%
Death08.04.01.0010.005708%
Dehydration14.05.05.0010.001477%
Diarrhoea07.02.01.0010.006906%
Discomfort08.01.08.0030.000246%Not Available
Drug ineffective08.06.01.0060.007466%Not Available
Dry mouth07.06.01.0020.000604%
Dry skin23.03.03.0010.002776%
Dyspepsia07.01.02.0010.000627%
Dysphagia07.01.06.0030.001254%
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.0040.000112%
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages